South Korean bio pharma Green Cross will build a cell therapy manufacturing center in China's Guizhou province to distribute products in China.
Green Cross said in a release that it has a growing portfolio of approved and investigational cell therapy projects including T cells, NK cells, dendritic cells and stem cells.
China, however, has lagged in approvals for new products as applications jumped in the past year, overwhelming efforts to reform the process. Green Cross did not disclose the amount it was investing, but noted that China's already large pharmaceutical market has been forecast to grow by 17% per year to become No. 2 in the world by 2020.
- here's the release